The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged.
GSK earlier this month agreed to pay $2.3 billion to end lawsuits alleging that Zantac caused cancer, despite the group not admitting liability. Stripping out the litigation costs, GSK said ...
“This [whistleblower] case is not about whether the NDMA in ranitidine causes cancer. … That issue is at the heart of personal injury lawsuits related to ranitidine causing individual consumers cancer ...
If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be entitled to legal compensation through a Zantac lawsuit. Due to increasing ...